Bravura Solutions Ltd. (AU000000BVS9)
XSTU 
Summary
AU000000BVS9 Chart
Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript
Bioventus Inc. (NASDAQ:BVS ) Q1 2025 Results Conference Call May 6, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Robbie Marcus - JPMorgan Operator Good day, and welcome to the Bioventus First Quarter 2025 Conference Call. [Operator Instructions] Please note this event is being recorded.
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates
Bioventus (BVS) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago.
Bioventus Reports First Quarter Financial Results
DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 29, 2025.
Bravura Solutions Ltd. Dividends
Bravura Solutions Ltd. Earnings
| 5 May 2025 Date | | 0.02 Cons. EPS | - EPS |
| 10 Mar 2025 Date | | 0.09 Cons. EPS | 0.15 EPS |
| 5 Nov 2024 Date | | 0.03 Cons. EPS | 0.06 EPS |
| 6 Aug 2024 Date | | 0.07 Cons. EPS | 0.19 EPS |
| 7 May 2024 Date | | - Cons. EPS | 0.07 EPS |
| 5 May 2025 Date | | 0.02 Cons. EPS | - EPS |
| 10 Mar 2025 Date | | 0.09 Cons. EPS | 0.15 EPS |
| 5 Nov 2024 Date | | 0.03 Cons. EPS | 0.06 EPS |
| 6 Aug 2024 Date | | 0.07 Cons. EPS | 0.19 EPS |
| 7 May 2024 Date | | - Cons. EPS | 0.07 EPS |
Bravura Solutions Ltd. (AU000000BVS9) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bravura Solutions Ltd. ever had a stock split?
Bravura Solutions Ltd. Profile
| Medical - Devices Industry | Healthcare Sector | Mr. Robert E. Claypoole CEO | XSTU Exchange | US09075A1088 ISIN |
| US Country | 930 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Bioventus Inc. is a pioneering medical device company that places a strong emphasis on innovating and providing treatments aimed at enhancing the body's intrinsic healing mechanisms. Operating both in the United States and internationally, the company has carved a niche for itself in the medical device industry by offering a wide range of products designed for pain management, surgical solutions, and restorative therapies. With its foundation in 2011 and headquarters in Durham, North Carolina, Bioventus stands as a beacon of advancement in leveraging medical technology to improve patient outcomes.
Products and Services
Pain Treatments: Bioventus' portfolio addresses non-surgical pain through injection therapies and peripheral nerve stimulation products. Key offerings include:
- Durolane: A treatment for knee osteoarthritis providing pain relief.
- GELSYN-3: A series of injections for knee osteoarthritis pain management.
- SUPARTZ: An injectable solution for knee osteoarthritis.
- Stimrouter: A device aimed at treating chronic peripheral pain.
Surgical Solutions: The company provides surgeons with innovative tools and biomaterials for bone and soft tissue procedures, featuring:
- Bone Graft Substitutes: Products like Osteoamp, Exponent matrix, Purebone, Signafuse bone graft, Interfuse bone graft, Osteomatrix+ synthetic bone graft, designed to stimulate bone healing.
- Ultrasonic Products: High-precision devices such as nexus ultrasonic surgical system, bonescalpel surgical solution, SonaStar, and SonicOne ultrasonic cleansing and debridement system for surgeries, including minimally invasive procedures.
- Extractor: A tool for autologous cell and bone marrow extraction to aid in bone healing.
- Reficio Bone Matrix: A novel bone graft substitute.
Restorative Therapies: Bioventus also addresses neurologic and musculoskeletal recovery, offering devices that aid in rehabilitation from strokes, multiple sclerosis, or central nervous system disorders. Products include:
- Exogen: A bone healing system.
- L300 GO: A system designed to improve foot drop conditions caused by central nervous system disorders.
- H200 Rehabilitation System: A solution to aid in regaining hand function.
- Vector: A body weight support system for gait and balance training.
- Bioness Integrated Therapy System: Offers comprehensive solutions for neurorehabilitation.
The company is also developing the Talisman Pulse Generator and Receiver, a potential breakthrough for peripheral nerve stimulation, showcasing Bioventus' commitment to ongoing innovation and improvement in the field of medical devices.
Contact Information
